IMHA Toolkit

Clinical protocols & thrombosis prevention awareness

Independent Educational Resource

Vet Portal → Equine IMHA Treatment Reference

Equine IMHA Treatment Reference

Clinical Basis: Derived from published equine pharmacology, case reports and retrospective clinical literature. The largest modern clinical cohort included 25 adult equids, but there is no widely accepted equine-specific IMHA treatment consensus equivalent to the canine ACVIM statement [Easton-Jones et al., 2021].

Equine Evidence Reference

⚠️

Important Clinical Notice This calculator is an educational dose-reference tool based on published veterinary literature. It does not provide a prescription or treatment plan. Drug choice, dose, contraindications, monitoring and treatment duration must be determined by a veterinary surgeon with direct knowledge of the individual patient and checked against current equine formulary information.

⚖️

Weight Parameters

Weight Entry

1. Immunosuppressive Considerations

Dexamethasone IV — Published Equine Reference

0.04 - 0.1 mg/kg

Dexamethasone is used systemically in horses for inflammatory and immune-mediated disease. The 0.04–0.1 mg/kg range shown here is a general equine glucocorticoid reference, not an equine IMHA regimen. Published controlled equine studies in other diseases commonly use around 0.04–0.05 mg/kg once daily; higher doses may be used in selected clinical contexts. Verify the intended dose and route against current equine formulary guidance.

Prednisolone Oral — Published Equine Reference

1.1 - 2.2 mg/kg

Oral prednisolone is generally preferred to oral prednisone in horses. Pharmacokinetic studies show that oral prednisone has poor systemic efficacy because little active prednisolone is produced, whereas oral prednisolone is well absorbed. The 1.1–2.2 mg/kg once-daily range is a general systemic equine reference used in published inflammatory-disease guidance, not an IMHA-specific consensus regimen.

⚠️ CORTICOSTEROID SAFETY NOTE: Systemic corticosteroid therapy in horses requires careful monitoring for adverse effects, including laminitis. Risk varies with the individual patient, dose, duration and concurrent disease. Monitoring and preventive measures should be determined by the attending veterinary surgeon.

📋 Treatment Escalation Considerations

Evidence guiding treatment escalation in equine IMHA is limited. Management should be individualised according to severity of anaemia and haemolysis, haemodynamic stability, transfusion requirements, associated disease, treatment response and adverse-effect risk. Specialist consultation may be appropriate in severe or refractory cases.

2. Antithrombotic Considerations

Thrombotic complications can occur in critically ill horses, but current equine IMHA literature does not establish that IMHA itself warrants routine thromboprophylaxis. The incidence, contribution of thrombosis to mortality and optimal prophylactic strategy remain poorly defined. Antithrombotic treatment should therefore be based on additional patient-specific thrombotic and bleeding risks and current equine critical-care guidance.

Unfractionated Heparin — Equine Literature Reference

80 - 100 U/kg SC per dose

UFH has been studied in horses at several different regimens. Published examples include approximately 80 U/kg SC every 8 hours and 100 U/kg SC every 12 hours, while older protocols used higher loading doses followed by tapering schedules. This calculator therefore shows a per-dose reference range only and does not establish a frequency or an IMHA-specific regimen. Dose, interval and monitoring must be selected by the treating veterinarian.

LMWH (Dalteparin) — Published Equine Reference

50 U/kg SC per dose

Dalteparin 50 U/kg SC has been studied in horses using both q12h and q24h schedules. In healthy horses, twice-daily administration maintained anti-Xa activity within or above a suggested thromboprophylactic range more consistently, whereas q24h activity fell below that range at about 16 hours. A separate clinical colic trial used 50 U/kg q24h. These data are not IMHA-specific, so this calculator reports the dose per administration rather than prescribing a fixed interval.

Aspirin — Antiplatelet Context

Aspirin has antiplatelet effects in horses, but the available evidence does not establish a standard aspirin regimen for thromboprophylaxis in equine IMHA. If antiplatelet therapy is considered, drug choice and dosing should be based on current equine pharmacology and the individual patient.

⚠️ Antithrombotic Combinations Antithrombotic drug selection and combinations should be individualised. Combining anticoagulant and antiplatelet therapies may increase bleeding risk and requires appropriate monitoring.

💡

Thrombotic risk in equine IMHA is incompletely characterised. The available equine IMHA literature is too limited to quantify the contribution of thrombosis to mortality or to define a universal prophylactic regimen.

⚠️ Please independently verify all calculated values before prescribing or administering medication.

📋 Equine Diagnostic & Clinical Guidelines

🔍 True Auto-Agglutination vs. Rouleaux

Rouleaux formation is prominent in equine blood and can mimic auto-agglutination. Saline dispersion testing can help distinguish rouleaux from persistent agglutination, but findings should be interpreted alongside the overall clinical and laboratory evidence for immune-mediated haemolysis.

🐴 Neonatal Isoerythrolysis (NI) Checks

In neonatal foals with acute haemolysis, neonatal isoerythrolysis should be considered according to age, colostrum exposure and clinical findings. Further ingestion of maternal colostrum may need to be prevented during the period of significant intestinal antibody absorption. Diagnosis and transfusion planning require veterinary assessment and blood compatibility testing.

📚 What does the equine evidence show? ▼

Published evidence for equine IMHA treatment consists largely of case reports, small case series and retrospective cohorts. In the largest modern cohort, 25 adult equids had IMHA, immune-mediated thrombocytopenia or both. Fifteen of 25 survived to discharge. Eight of nine equids classified as having primary immune-mediated disease survived, compared with seven of 16 with secondary disease, and neoplasia was significantly more common in affected equids than controls. The study was retrospective and descriptive and does not establish a standard treatment protocol [Easton-Jones et al., 2021].

Evidence hierarchy matters on this page The glucocorticoid and heparin calculations below are drawn from general equine pharmacology and disease-specific studies outside IMHA. They are included as dose-reference mathematics, not as a recommended equine IMHA protocol. The 25-equid retrospective IMHA/IMTP cohort describes outcomes and associated disease but does not validate any particular drug regimen [Easton-Jones et al., 2021].

Published Dose References

Dexamethasone IV (Acute Stage): Weight (kg) × 0.04 mg to 0.1 mg/kg once daily (IV q24h)

Prednisolone Oral Reference: Weight (kg) × 1.1 mg to 2.2 mg/kg once daily — general equine systemic reference

Unfractionated Heparin (UFH): Weight (kg) × 80 U to 100 U/kg subcutaneously per dose — published equine reference; interval varies by protocol

LMWH (Dalteparin) Protocol: Weight (kg) × 50 U/kg subcutaneously per dose — q12h and q24h schedules have been studied

Sources: published equine pharmacology, antithrombotic studies, case reports and retrospective clinical literature. No equine-specific IMHA treatment consensus is implied. View equine IMHA evidence. EDUCATIONAL DOSE-REFERENCE SUPPORT — VERIFY AGAINST CURRENT EQUINE FORMULARY SOURCES

Evidence Library

Review the principal equine IMHA cohort and supporting clinical literature.

Open Evidence Library →